Editas Medicine, Inc.
Cas9 fusion molecules, gene editing systems, and methods of use thereof

Last updated:

Abstract:

Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.

Status:
Grant
Type:

Utility

Filling date:

12 Apr 2017

Issue date:

1 Feb 2022